Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age superior or equal 18 years~* primitive ovarian adenocarcinoma histologically confirmed~* or peritoneal or fallopian tube adenocarcinoma histologically confirmed~* Progression or relapse within 12 months after the end of first line of platin based chemotherapy~* association in first line with other anticancer agent is allowed (taxanes, anthracyclines, alkylants or gemcitabine) and with an anti-angiogenic (bevacizumab, sunitinib).~* intra-peritoneal chemotherapy in first line is possible~* No previous treatment with HER inhibitors (ex : gefitinib)~* HER status not necessary~* measurable lesions (RECIST criteria). and/or CA125 value higher than 2 fold the normal value or CA125 higher than 2 fold nadir value (if no normalized) proved by two samples distant of 1 month~* OMS inferior or equal 2.~* biological parameters as follow: creatininemia ≤ 150 µmol/L or clearance ≥ 50 mL/min,bilirubin ≤ 1,5 LNS,transaminases and or alcalin phosphatases ≤ 2 LNS without hepatic metastasis or ≤ 3 LNS if hepatic metastasis,neutrophils ≥ 1,5.109/L,plaquettes ≥ 100.109/L.~* normal FEV~* No previous treatment by chemotherapy, hormonotherapy, immunotherapy or radiotherapy within 4 weeks before inclusion~* No concomitant treatment forbidden with lapatinib.~* No previous treatment by Amiodarone in 6 months before inclusion~* signed informed consent~Exclusion Criteria:~* Previous treatment with :~  * intensive chemotherapy with autograft~ * two lignes of chemotherapy~ * previous total abdominal irradiation~ * previous chemotherapy with anti-HER treatment~* History of brain or meningitis metastasis uncontrolled.~* Malignancies except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer.~* uncontrolled infectious pathology~* uncontrolled cardiovascular disease~* Patients with an active intestinal occlusion not permit oral treatment~* known hypersensibility to topotecan and its excipients~* Woman of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period~* Individual deprived of liberty

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).